Ionis Pharmaceuticals

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Why Robinhood?

Robinhood gives you the tools you need to put your money in motion. You can buy or sell IONS and other ETFs, options, and stocks.

About IONS

Ionis Pharmaceuticals, Inc. engages in the development and commercialization of human therapeutic drugs using antisense technology. The company was founded by Stanley T. 

CEO
Brett P. Monia
CEOBrett P. Monia
Employees
1,069
Employees1,069
Headquarters
Carlsbad, California
HeadquartersCarlsbad, California
Founded
1989
Founded1989
Employees
1,069
Employees1,069

IONS Key Statistics

Market cap
13.02B
Market cap13.02B
Price-Earnings ratio
-46.92
Price-Earnings ratio-46.92
Dividend yield
Dividend yield
Average volume
1.82M
Average volume1.82M
High today
$83.23
High today$83.23
Low today
$79.30
Low today$79.30
Open price
$82.17
Open price$82.17
Volume
2.67M
Volume2.67M
52 Week high
$86.15
52 Week high$86.15
52 Week low
$23.95
52 Week low$23.95

Stock Snapshot

As of today, Ionis Pharmaceuticals(IONS) shares are valued at $80.30. The company's market cap stands at 13.02B, with a P/E ratio of -46.92.

On 2026-01-11, Ionis Pharmaceuticals(IONS) stock moved within a range of $79.30 to $83.23. With shares now at $80.30, the stock is trading +1.3% above its intraday low and -3.5% below the session's peak.

Trading volume for Ionis Pharmaceuticals(IONS) stock has reached 2.67M, versus its average volume of 1.82M.

The stock's 52-week range extends from a low of $23.95 to a high of $86.15.

The stock's 52-week range extends from a low of $23.95 to a high of $86.15.

IONS News

Simply Wall St 3d
Ionis Pharmaceuticals Is Up 5.1% After Hepatitis B Drug Hits Phase 3 Goals - Has The Bull Case Changed?

GSK and Ionis Pharmaceuticals recently reported that their experimental hepatitis B therapy bepirovirsen met primary endpoints in two Phase 3 trials, achieving...

Ionis Pharmaceuticals Is Up 5.1% After Hepatitis B Drug Hits Phase 3 Goals - Has The Bull Case Changed?
Benzinga 4d
GSK/Ionis Partnered Investigational Drug Shows Strong Results In Large Hepatitis B Studies

Ionis Pharmaceuticals Inc. (NASDAQ:IONS) partner GSK Plc (NYSE:GSK) on Wednesday shared data from two pivotal Phase 3 studies, B-Well 1 and B-Well 2, of bepirov...

GSK/Ionis Partnered Investigational Drug Shows Strong Results In Large Hepatitis B Studies
TipRanks 4d
Ionis partner GSK reports B-Well 1, B-Well 2 studies met primary endpoint

Ionis Pharmaceuticals (IONS) partner GSK (GSK) announced results from two pivotal Phase 3 studies, B-Well 1 and B-Well 2, evaluating the safety and efficacy of...

Analyst ratings

71%

of 24 ratings
Buy
70.8%
Hold
29.2%
Sell
0%

More IONS News

Simply Wall St 5d
Assessing Ionis Pharmaceuticals Valuation After Analyst Optimism And FDA Approval Of Tryngolza

Recent optimism from several Wall Street firms toward Ionis Pharmaceuticals (IONS) has been tied to its broad RNA-focused pipeline and the recent FDA approval o...

Assessing Ionis Pharmaceuticals Valuation After Analyst Optimism And FDA Approval Of Tryngolza
TipRanks 6d
Ionis Pharmaceuticals price target raised to $100 from $82 at Wells Fargo

Wells Fargo raised the firm’s price target on Ionis Pharmaceuticals (IONS) to $100 from $82 and keeps an Overweight rating on the shares. Following a strong 202...

People also own

Based on the portfolios of people who own IONS. This list is generated using Robinhood data, and it’s not a recommendation.
All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer.